ATE437944T1 - Für das dystrophin-minigen kodierende dna- sequenzen und verfahren zu deren verwendung - Google Patents

Für das dystrophin-minigen kodierende dna- sequenzen und verfahren zu deren verwendung

Info

Publication number
ATE437944T1
ATE437944T1 AT01934920T AT01934920T ATE437944T1 AT E437944 T1 ATE437944 T1 AT E437944T1 AT 01934920 T AT01934920 T AT 01934920T AT 01934920 T AT01934920 T AT 01934920T AT E437944 T1 ATE437944 T1 AT E437944T1
Authority
AT
Austria
Prior art keywords
dystrophin
present
provides
minigen
dna sequences
Prior art date
Application number
AT01934920T
Other languages
English (en)
Inventor
Xiao Xiao
Original Assignee
Asklepios Biopharmaceutical In
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Asklepios Biopharmaceutical In filed Critical Asklepios Biopharmaceutical In
Application granted granted Critical
Publication of ATE437944T1 publication Critical patent/ATE437944T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4707—Muscular dystrophy
    • C07K14/4708—Duchenne dystrophy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/025—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a parvovirus

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AT01934920T 2000-04-28 2001-04-27 Für das dystrophin-minigen kodierende dna- sequenzen und verfahren zu deren verwendung ATE437944T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20077700P 2000-04-28 2000-04-28
PCT/US2001/013677 WO2001083695A2 (en) 2000-04-28 2001-04-27 Dna sequences encoding dystrophin minigenes and methods of use thereof

Publications (1)

Publication Number Publication Date
ATE437944T1 true ATE437944T1 (de) 2009-08-15

Family

ID=22743139

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01934920T ATE437944T1 (de) 2000-04-28 2001-04-27 Für das dystrophin-minigen kodierende dna- sequenzen und verfahren zu deren verwendung

Country Status (9)

Country Link
US (2) US7001761B2 (de)
EP (1) EP1287125B1 (de)
CN (1) CN100422320C (de)
AT (1) ATE437944T1 (de)
AU (1) AU2001261063A1 (de)
CA (1) CA2407309C (de)
DE (1) DE60139394D1 (de)
ES (1) ES2330615T3 (de)
WO (1) WO2001083695A2 (de)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2407309C (en) * 2000-04-28 2011-08-02 Xiao Xiao Dna sequences encoding dystrophin minigenes and methods of use thereof
DE60134786D1 (de) 2000-10-06 2008-08-21 Univ Michigan Mini-dystrophin nukleinsäure- und peptidsequenzen
DE60231975D1 (de) * 2001-05-24 2009-05-28 Genzyme Corp Muskelspezifische expressionsvektoren
CA2507125C (en) 2002-11-25 2014-04-22 Masafumi Matsuo Ena nucleic acid pharmaceuticals capable of modifying splicing of mrna precursors
AU2003225410A1 (en) 2003-03-21 2004-10-11 Academisch Ziekenhuis Leiden Modulation of exon recognition in pre-mrna by interfering with the secondary rna structure
WO2005118611A2 (en) * 2004-01-23 2005-12-15 The Trustees Of The University Of Pennsylvania Microutrophin and uses thereof
EP2500430B1 (de) 2004-06-28 2017-03-08 The University Of Western Australia Antisense-Oligonukleotide zur Induktion von Exon-Skipping sowie Verfahren zur Verwendung davon
WO2007123391A1 (en) 2006-04-20 2007-11-01 Academisch Ziekenhuis Leiden Therapeutic intervention in a genetic disease in an individual by modifying expression of an aberrantly expressed gene.
EP1857548A1 (de) 2006-05-19 2007-11-21 Academisch Ziekenhuis Leiden Mittel und Verfahren zur Induktion von Exon-skipping
WO2008018795A1 (en) 2006-08-11 2008-02-14 Prosensa Technologies B.V. Methods and means for treating dna repeat instability associated genetic disorders
US7863017B2 (en) * 2006-12-01 2011-01-04 Wisconsin Alumni Research Foundation TAT-utrophin as a protein therapy for dystrophinopathies
JP5575486B2 (ja) * 2007-01-18 2014-08-20 ユニヴァーシティ オブ ミズーリー−コロンビア 筋鞘にｎＮＯＳを回復させる合成ミニ／ミクロジストロフィン遺伝子
US20080221027A1 (en) * 2007-03-09 2008-09-11 The Regents Of The University Of California Composition and Methods for the Treatment of Duchene Muscular Dystrophy
NZ582521A (en) 2007-07-12 2011-09-30 Prosensa Technologies Bv A conjugate comprising the amino acid sequence LGAQSNF for targeting compounds to muscle tissue
USRE48468E1 (en) 2007-10-26 2021-03-16 Biomarin Technologies B.V. Means and methods for counteracting muscle disorders
WO2009054725A2 (en) 2007-10-26 2009-04-30 Academisch Ziekenhuis Leiden Means and methods for counteracting muscle disorders
NZ587178A (en) 2008-02-08 2011-11-25 Prosensa Holding Bv Methods and means for treating dna repeat instability associated genetic disorders
US20090280103A1 (en) * 2008-04-04 2009-11-12 Martin Flueck Regulation of muscle repair
EP2119783A1 (de) 2008-05-14 2009-11-18 Prosensa Technologies B.V. Verfahren für effizientes Exon (44)-Skipping bei Duchenne-Muskeldystrophie und entsprechende Mittel
KR20250016146A (ko) 2008-10-24 2025-02-03 사렙타 쎄러퓨틱스 인코퍼레이티드 Dmd를 위한 다중 엑손 스키핑 조성물
AU2010239779A1 (en) 2009-04-24 2011-11-17 Prosensa Technologies B.V. Oligonucleotide comprising an inosine for treating DMD
KR102239374B1 (ko) 2009-11-12 2021-04-14 더 유니버시티 오브 웨스턴 오스트레일리아 안티센스 분자 및 이를 이용한 질환 치료방법
WO2011100505A2 (en) 2010-02-11 2011-08-18 Recombinetics, Inc. Methods and materials for producing transgenic artiodactyls
US10920242B2 (en) 2011-02-25 2021-02-16 Recombinetics, Inc. Non-meiotic allele introgression
EP4043039A1 (de) 2012-01-27 2022-08-17 BioMarin Technologies B.V. Rna-modulierende oligonukleotide mit verbesserten eigenschaften zur behandlung der duchenne- und becker-muskeldystrophie
WO2014081855A1 (en) * 2012-11-20 2014-05-30 Universite De Montreal Methods and compositions for muscular dystrophies
CN105378081B (zh) 2013-03-14 2019-06-14 萨勒普塔医疗公司 用于治疗肌营养不良的外显子跳跃组合物
EP3662912B1 (de) 2013-03-15 2025-12-03 Sarepta Therapeutics, Inc. Verbesserte eteplirsen dosierungen zur behandlung von duchenne muskeldystrophie
GB201507842D0 (en) * 2015-05-07 2015-06-17 New Royal Holloway & Bedford Production of large-sized microdystrophins in an AAV-based vector configuration
LT3442602T (lt) 2016-04-15 2025-06-10 Research Institute At Nationwide Children's Hospital Mikrodistrofino adeno-asocijuoto viruso vektoriaus pateikimas raumenų distrofijos gydymui
WO2017221145A1 (en) * 2016-06-21 2017-12-28 Bamboo Therapeutics, Inc. Optimized mini-dystrophin genes and expression cassettes and their use
US11338045B2 (en) 2017-03-17 2022-05-24 Newcastle University Adeno-associated virus vector delivery of a fragment of micro-dystrophin to treat muscular dystrophy
EP3697915A4 (de) 2017-10-18 2021-12-08 Research Institute at Nationwide Children's Hospital Adeno-assoziierte virusvektorverabreichung von muskelspezifischem mikrodystrophin zur behandlung von muskeldystrophie
JP7575273B2 (ja) * 2018-04-16 2024-10-29 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア デュシェンヌ型筋ジストロフィーを治療するための組成物及び方法
DK3807413T3 (da) 2018-06-18 2025-08-25 Res Inst Nationwide Childrens Hospital Adenoassocieret virusvektorfremføring af muskelspecifik mikrodystrofin til behandling af muskeldystrofi
BR112021009481A2 (pt) * 2018-11-16 2021-08-17 Astellas Pharma Inc. método para tratamento da distrofia muscular direcionando gene de utrofina.
CA3142194A1 (en) 2019-05-30 2020-12-03 Solid Biosciences Inc. Recombinant herpesvirales vector
CA3144864A1 (en) 2019-06-27 2020-12-30 Pfizer Inc. Methods of treating duchenne muscular dystrophy using aav mini-dystrophin gene therapy
AU2020372429A1 (en) * 2019-10-25 2022-04-28 Audentes Therapeutics, Inc. Compositions and methods for treating glycogen storage disorders
CA3155381A1 (en) 2019-11-06 2021-05-14 Association Institut De Myologie Combined therapy for muscular diseases
US20230158173A1 (en) * 2020-03-20 2023-05-25 University Of Florida Research Foundation, Inc. Gene therapy for cockayne syndrome
CA3174312A1 (en) 2020-04-29 2021-11-04 Glen BANKS Miniaturized dystrophins having spectrin fusion domains and uses thereof
EP4240861A1 (de) 2020-11-03 2023-09-13 Pfizer Inc. Verfahren zur reinigung von aav-vektoren durch anionenaustauschchromatografie
MX2023007612A (es) 2020-12-23 2023-07-12 Pfizer Metodos para purificacion de vectores aav por cromatografia de afinidad.
RU2767335C1 (ru) * 2021-03-02 2022-03-17 Общество с ограниченной ответственностью «Марлин Биотех» Химерные белки на основе утрофина и дистрофина человека и их применение для лечения миодистрофии Дюшенна
CA3218333A1 (en) 2021-04-05 2022-10-13 Solid Biosciences Inc. Recombinant herpesvirales vector
CN114316070B (zh) * 2021-12-29 2022-11-15 上海勉亦生物科技有限公司 用于治疗肌营养不良症的转基因表达盒
EP4215614A1 (de) 2022-01-24 2023-07-26 Dynacure Kombinationstherapie für dystrophin-verwandte krankheiten

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0228458B2 (de) 1985-07-05 1997-10-22 Whitehead Institute For Biomedical Research Expression von fremdem genetischem material in epithelzellen
US5239060A (en) * 1986-07-25 1993-08-24 The Children's Medical Center Corporation Muscular dystrophy protein, dystrophin
JP3082204B2 (ja) 1988-09-01 2000-08-28 ホワイトヘッド・インスティチュート・フォー・バイオメディカル・リサーチ 両栄養性および環境栄養性宿主域を持つ組換え体レトロウイルス
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US5173414A (en) 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
US5661033A (en) 1992-11-25 1997-08-26 The Board Of Trustees Of The Leland Stanford Junior University Gene transfer using herpes virus vectors as a tool for neuroprotection
US5985846A (en) 1995-06-07 1999-11-16 Baylor College Of Medicine Gene therapy for muscular dystrophy
GB9622174D0 (en) * 1995-12-19 1996-12-18 Medical Res Council Gene expression
EP1696036B1 (de) * 1996-09-06 2010-04-21 The Trustees of The University of Pennsylvania Rekombinante AAV zur Herstellung eines Medikaments für die Gentherapie von Muskelzellen
US5994132A (en) 1996-10-23 1999-11-30 University Of Michigan Adenovirus vectors
US6207455B1 (en) 1997-05-01 2001-03-27 Lung-Ji Chang Lentiviral vectors
US6410300B1 (en) * 1998-01-12 2002-06-25 The University Of North Carolina At Chapel Hill Methods and formulations for mediating adeno-associated virus (AAV) attachment and infection and methods for purifying AAV
JPH11318467A (ja) * 1998-05-08 1999-11-24 Japan Science & Technology Corp 短縮型ジストロフィン
AU7895700A (en) * 1999-10-15 2001-04-30 Dalhousie University Method and vector for producing and transferring trans-spliced peptides
US20020076754A1 (en) * 2000-04-20 2002-06-20 Liangwu Sun Overcoming AAV vector size limitation through viral DNA hetero-dimerization
CA2407309C (en) * 2000-04-28 2011-08-02 Xiao Xiao Dna sequences encoding dystrophin minigenes and methods of use thereof
DE60134786D1 (de) * 2000-10-06 2008-08-21 Univ Michigan Mini-dystrophin nukleinsäure- und peptidsequenzen
CN1411590A (zh) 2000-11-07 2003-04-16 皇家菲利浦电子有限公司 用于在信息信号中嵌入水印的方法和装置

Also Published As

Publication number Publication date
AU2001261063A1 (en) 2001-11-12
EP1287125A4 (de) 2005-04-27
US7001761B2 (en) 2006-02-21
US20030171312A1 (en) 2003-09-11
CN1439051A (zh) 2003-08-27
CA2407309A1 (en) 2001-11-08
ES2330615T3 (es) 2009-12-14
CA2407309C (en) 2011-08-02
WO2001083695A2 (en) 2001-11-08
WO2001083695A3 (en) 2002-03-07
US7510867B2 (en) 2009-03-31
CN100422320C (zh) 2008-10-01
WO2001083695A9 (en) 2002-12-12
EP1287125B1 (de) 2009-07-29
EP1287125A2 (de) 2003-03-05
US20060073586A1 (en) 2006-04-06
DE60139394D1 (de) 2009-09-10

Similar Documents

Publication Publication Date Title
ATE437944T1 (de) Für das dystrophin-minigen kodierende dna- sequenzen und verfahren zu deren verwendung
FR21C1037I1 (fr) Clades de virus adéno associés (aav), séquences, vecteurs les contenant et leurs utilisations
Brosius RNAs from all categories generate retrosequences that may be exapted as novel genes or regulatory elements
IL234063A0 (en) Sequences of adenoid virus serological type 7 and recombinant viruses containing them
CY1109746T1 (el) Χιμαιρικα μορια snrna που φερουν αντιπληροφοριακες αλληλουχιες εναντι των συνδεσμων συρραφης του γονιδιου δυστροφινης και θεραπευτικες εφαρμογες αυτων
NO990025L (no) Hamster-EF-1<alfa> transkripsjonsregulatorisk DNA
ATE362542T1 (de) Nukleinsäuresequenzen des adeno-assoziierten virus des serotyps i, und vektoren und wirtszellen, die diese enthalten
GB0124317D0 (en) Biological products
ATE318923T1 (de) Doppelsträngige parvovirus-vektoren
DE69632466D1 (de) Lösung die chaotropische mittel enthält und verwendung dieser lösung in verfahren zur isolierung von dna, rna und proteinen
DK1569661T3 (da) Antisense design
ATE484596T1 (de) Mutantes herpes-simplex-virus und verwendung davon bei der behandlung von plattenepithelkarzinom
Chahal et al. miR-122–based therapies select for three distinct resistance mechanisms based on alterations in RNA structure
ATE172642T1 (de) Impfstoffe und verfahren zu ihrer herstellung
CY1106369T1 (el) Μεθοδος ταχειας τυποποιησης μικροοργανισμων με ηλεκτροφορηση πηκτης παλλομενου πεδιου με την οποια τα δειγματα παρασκευαζονται σε ενα εγκλειομενο σε αυτοκλειστο και ευκαμπτο καλουπι
EP1151140A4 (de) Prostata-spezifische gene zur diagnose, prognose und behandlung von prostata-krebs
ATE78301T1 (de) Molekulare genetische sonde und verfahren zu ihrer herstellung, testmethode und satz in denen diese molekulare genetische sonde gebraucht wird.
ATE461283T1 (de) Neue vollständige genomische rna des japanenzephalitis-virus, infektiöse jev cdna daraus und deren verwendung
DE50110597D1 (de) L-Aminosäure-Oxidase aus Rhodococcus-Arten
Holloway et al. Rabies virus-induced RNA synthesis in BHK21 cells
NO20055669L (no) Familie av utskilte proteiner
ATE427959T1 (de) Gereinigtes sr-p70 protein
DK0643719T3 (da) Nukleinsyresekvenser, som koder for eller er komplementære til nukleinsyresekvenser, som koder for interleukin 9-receptor
DE60130465D1 (de) Mutierte muskelspezifische enhancer
ATE335073T1 (de) Replikationsprozess des hepatitis c virus

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties